Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| OPTH | 6-K | bullish | 6/10 | Optimi Health announced plans for a Health Canada-authorized Phase 3 clinical trial evaluating MDMA-assisted therapy for | Sep 16, 2026 |
| OGEN | 8-K | neutral | 3/10 | Oragenics filed an 8-K announcing its Chief Medical Officer will present at the IPAC-RS 2026 Nasal Innovation Forum, hig | Sep 16, 2026 |
| MAIA | PRESS-RELEASE | bullish | 7/10 | MAIA Biotechnology dosed the first U.S. patient in the Phase 2 THIO-101 trial expansion for ateganosine in third-line NS | Sep 16, 2026 |
| MYGN | 8-K | neutral | 3/10 | Myriad Genetics announced the departure of Chief Commercial Officer Brian Donnelly (effective Sept 16, 2026, with a tran | Sep 16, 2026 |
| CRDL | 6-K | bullish | 5/10 | Cardiol Therapeutics announced receipt of over USD $7 million from the exercise of common share purchase warrants, exten | Sep 16, 2026 |
| MYGN | PRESS-RELEASE | neutral | 3/10 | Myriad Genetics announced the promotion of Vishal Sikri to EVP-Commercial, replacing departing CCO Brian Donnelly. The c | Sep 16, 2026 |
| ALLR | 8-K | bullish | 5/10 | Allarity Therapeutics announced the Japan Patent Office granted patent No. 7917283 covering its stenoparib-specific Drug | Sep 16, 2026 |
| VIVS | PRESS-RELEASE | neutral | 5/10 | VivoSim Labs presented new clinical benchmark data at EUROTOX 2026 demonstrating its NAMkind™ 3D human liver and intesti | Sep 16, 2026 |
| ARTL | PRESS-RELEASE | bullish | 6/10 | Artelo Biosciences announced nonclinical results showing its oral dual cannabinoid agonist ART27.13 produced ~20% weight | Sep 16, 2026 |
| KRSA | SC 13G | neutral | 3/10 | Wellington Biomedical Innovation Master Investors (Cayman) II L.P. filed a Schedule 13G disclosing a 6.1% passive stake | Sep 16, 2026 |
| XBIO | 8-K | bullish | 7/10 | Xenetic Biosciences (XBIO) entered into a definitive share exchange agreement to acquire all outstanding shares of Sante | Sep 16, 2026 |
| KMDA | EFFECT | neutral | 3/10 | Kamada Ltd's shelf registration statement on Form F-3 (File No. 333-298814) was declared effective by the SEC on Septemb | Sep 16, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a Form 6-K on September 16, 2026, solely to submit an exhibit (Exhibit 99.1) regarding an ap | Sep 16, 2026 |
| ANL | EFFECT | bullish | 7/10 | Adlai Nortye Group Ltd.'s registration statement on Form S-1 (File No. 333-294173) was declared effective by the SEC on | Sep 16, 2026 |
| NRXP | 8-K | bullish | 5/10 | NRx Pharmaceuticals announced that the FDA reclassified its ANDA amendment for preservative-free ketamine (NRX-100) from | Sep 16, 2026 |
| NAMS | INSIDER-BUY | bullish | 5/10 | CEO Michael Davidson purchased $227K of NAMS stock on the open market at $22.65/share, a standalone conviction buy. This | Sep 16, 2026 |
| RVMD | CLUSTER | neutral | 2/10 | Two insiders at Revolution Medicines sold shares in a cluster totaling ~$1.37M in open-market sales, with additional der | Sep 16, 2026 |
| INBX | CLUSTER | neutral | 4/10 | Inhibrx Biosciences (INBX) insiders showed mixed activity in early September 2026: three directors/executives made open- | Sep 16, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | CEO Martine Rothblatt sold ~$1.37M in open-market shares on Sept 14, 2026, part of a larger cluster of option exercises | Sep 16, 2026 |
| CYTK | CLUSTER | bearish | 5/10 | Cytokinetics CEO Robert Blum sold $7.3M in open-market shares (97,926 shares at $69.33 and 7,500 at $73.44) alongside di | Sep 16, 2026 |
| ABBV | COURT-RULING | neutral | 5/10 | New Mexico federal court denied AbbVie's motion for a preliminary injunction against H.B. 78, a state law restricting ma | Sep 15, 2026 |
| NTHI | CLUSTER | neutral | 5/10 | No summary provided | Sep 15, 2026 |
| RKDA | 8-K | neutral | 3/10 | Arcadia Biosciences filed an 8-K covering Item 5.02 (director/officer changes), Item 5.07 (shareholder vote results), an | Sep 15, 2026 |
| BHST | 6-K | neutral | 3/10 | BioHarvest Sciences filed two 6-K reports in a short window. The first is a routine press release announcing a corporate | Sep 15, 2026 |
| RVMD | 144 | neutral | 4/10 | Two Form 144 notices filed 2026-09-15 signal insider selling intent at Revolution Medicines. Margaret A. Horn (Officer) | Sep 15, 2026 |
| RVMD | 144 | neutral | 2/10 | Stephen Michael Kelsey, an officer of Revolution Medicines, Inc., filed a Form 144 indicating intent to sell 5,415 share | Sep 15, 2026 |
| ABT | COURT-RULING | neutral | 1/10 | This is a routine procedural order in a consumer class action against Abbott Diabetes Care and Abbott Laboratories regar | Sep 15, 2026 |
| SPRY | COURT-RULING | neutral | 2/10 | The court denied ARS Pharmaceuticals' objection to a magistrate order granting the plaintiff leave to file a third amend | Sep 15, 2026 |
| CSTL | CLUSTER | neutral | 2/10 | Two Castle Biosciences insiders, including the CEO and CCO, sold a combined $110K in shares over a week. The CEO's sale | Sep 15, 2026 |
| ANIP | CLUSTER | neutral | 3/10 | Three ANIP insiders, including the CEO and General Counsel, sold a total of ~$490K in open-market sales over a one-week | Sep 15, 2026 |